2020
Risk factors for liposomal bupivacaine resistance after total hip or knee arthroplasties: a retrospective observational cohort in 237 patients
Buzin S, Gianakos A, Li D, Viola A, Elkattawy S, Keller D, Yoon R, Liporace F. Risk factors for liposomal bupivacaine resistance after total hip or knee arthroplasties: a retrospective observational cohort in 237 patients. Patient Safety In Surgery 2020, 14: 6. PMID: 32015758, PMCID: PMC6990520, DOI: 10.1186/s13037-020-0230-4.Peer-Reviewed Original ResearchHigher pain scoresLiposomal bupivacainePain scoresRisk factorsPain managementOpioid useYounger patientsRandomized trialsTotal hipKnee arthroplastyRevision arthroplastyMulti-modal pain managementRetrospective observational cohortPain management protocolTotal knee arthroplastyPostoperative painObservational cohortActive smokersOutcomes RegistryInfection/Primary THAResultsA totalRetrospective analysisExclusion criteriaBupivacaine
2018
Limited evidence for adipose‐derived stem cell therapy on the treatment of osteoarthritis
Hurley E, Yasui Y, Gianakos A, Seow D, Shimozono Y, Kerkhoffs G, Kennedy J. Limited evidence for adipose‐derived stem cell therapy on the treatment of osteoarthritis. Knee Surgery, Sports Traumatology, Arthroscopy 2018, 26: 3499-3507. PMID: 29713784, DOI: 10.1007/s00167-018-4955-x.Peer-Reviewed Original ResearchConceptsStromal vascular fractionPlatelet-rich plasmaTreatment of osteoarthritisClinical outcomesSystematic reviewForm of SVFUse of SVFAdipose-derived stem cell therapyEffects of ADSCsIncidence of swellingFavorable clinical outcomeLevel IV studiesCochrane Library databasesEffects of AdiposeDonor siteStem cell therapySVF injectionComplication rateBiological adjuvantsClinical studiesLevel IVExclusion criteriaLibrary databasesSide effectsAdipose tissue
2017
Clinical application of concentrated bone marrow aspirate in orthopaedics: A systematic review
Gianakos A, Sun L, Patel J, Adams D, Liporace F. Clinical application of concentrated bone marrow aspirate in orthopaedics: A systematic review. World Journal Of Orthopedics 2017, 8: 491-506. PMID: 28660142, PMCID: PMC5478493, DOI: 10.5312/wjo.v8.i6.491.Peer-Reviewed Original ResearchConcentrated bone marrow aspirateBone marrow aspirateTendon repairTendon injuriesMarrow aspiratesCartilaginous lesionsSystematic reviewClinical settingFull-thickness chondral lesionsSignificant clinical improvementQuality of evidenceInclusion/exclusion criteriaLevel of evidenceStandardized outcome measuresMagnetic resonance imagingClinical improvementAdjunctive treatmentBone unionDecreased riskLower incidenceChondral lesionsOutcome measuresExclusion criteriaHealing rateOsteochondral lesions
2015
Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday
Villa J, Gianakos A, Lane J. Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday. HSS Journal ® 2015, 12: 66-73. PMID: 26855630, PMCID: PMC4733702, DOI: 10.1007/s11420-015-9469-1.Peer-Reviewed Original ResearchRecent fragility fractureDrug holidayBisphosphonate treatmentFragility fracturesBone deficiencyQuestions/PurposesThe purposeHigh fracture riskBone turnover rateRisk of fractureBone mass measurementsBisphosphonate therapyDrug discontinuationPeer-reviewed journalsCase seriesDrug therapyFracture riskPurposesThe purposeClinical trialsInclusion criteriaCase controlExclusion criteriaMethodsA reviewHuman studiesPatientsElectronic databases